Remove 2027 Remove Diabetes Remove Packaging
article thumbnail

STAT+: Pharmalittle: We’re reading about Moderna R&D cuts, Lilly plant investments and more

STAT

This calls for celebration with a cup of stimulation, and we are opening a new package of pecan pie for the occasion. billion, between 2024 and 2027 in a concession to investors who have viewed the company’s outlays following its pandemic-era windfall as profligate, STAT writes. Sound familiar? Have a great day, everyone.

Packaging 140
article thumbnail

Eli Lilly plans to invest $450m at production site in Research Triangle Park

Pharmafile

Lilly’s expansion is set to include the addition of further parenteral filling, device assembly and packaging capacity in order to meet the growing demand for the company’s incretin-based diabetes treatments and medications. read more

article thumbnail

Moving towards oral delivery of biologics

European Pharmaceutical Review

1 Used to treat a range of chronic diseases (eg, diabetes, rheumatoid arthritis, psoriasis, Crohn’s disease, haemophilia, etc), it is projected that the sales of biologics will rise from $380 billion in 2022 to $416 billion in 2023, and to almost $600 billion in 2027. Diabetes Therapy. The Business Research Company.